Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93

Beat Thürlimann, Karen N. Price, Richard D. Gelber, Stig B. Holmberg, Diana Crivellari, Marco Colleoni, John Collins, John F. Forbes, Monica Castiglione-Gertsch, Alan S. Coates, Aron Goldhirsch

Research output: Contribution to journalArticle

Abstract

Introduction: International Breast Cancer Study Group (IBCSG) Trial 11-93 is the largest trial evaluating the role of the addition of chemotherapy to ovarian function suppression/ablation (OFS) and tamoxifen in premenopausal patients with endocrine-responsive early breast cancer. Methods: IBCSG Trial 11-93 is a randomized trial comparing four cycles of adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to OFS and 5 years of tamoxifen versus OFS and tamoxifen without chemotherapy in premenopausal patients with node-positive, endocrine-responsive early breast cancer. There were 174 patients randomized from May 1993 to November 1998. The trial was closed before the target accrual was reached due to low accrual rate. Results: Patients randomized tended to have lower risk node-positive disease and the median age was 45. After 10 years median follow up, there remains no difference between the two randomized treatment groups for disease-free (hazard ratio = 1.02 (0.57-1.83); P = 0.94) or overall survival (hazard ratio = 0.97 (0.44-2.16); P = 0.94). Conclusion: This trial, although small, offers no evidence that AC chemotherapy provides additional disease control for premenopausal patients with lower-risk node-positive endocrine-responsive breast cancer who receive adequate adjuvant endocrine therapy. A large trial is needed to determine whether chemotherapy adds benefit to endocrine therapy for this population.

Original languageEnglish
Pages (from-to)137-144
Number of pages8
JournalBreast Cancer Research and Treatment
Volume113
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Breast Neoplasms
Drug Therapy
Tamoxifen
Epirubicin
Adjuvant Chemotherapy
Doxorubicin
Cyclophosphamide
Therapeutics
Survival
Population

Keywords

  • Breast cancer
  • Estrogen receptor
  • Goserelin
  • Ovarian ablation
  • Ovarian function suppression
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93. / Thürlimann, Beat; Price, Karen N.; Gelber, Richard D.; Holmberg, Stig B.; Crivellari, Diana; Colleoni, Marco; Collins, John; Forbes, John F.; Castiglione-Gertsch, Monica; Coates, Alan S.; Goldhirsch, Aron.

In: Breast Cancer Research and Treatment, Vol. 113, No. 1, 01.2009, p. 137-144.

Research output: Contribution to journalArticle

Thürlimann, Beat ; Price, Karen N. ; Gelber, Richard D. ; Holmberg, Stig B. ; Crivellari, Diana ; Colleoni, Marco ; Collins, John ; Forbes, John F. ; Castiglione-Gertsch, Monica ; Coates, Alan S. ; Goldhirsch, Aron. / Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93. In: Breast Cancer Research and Treatment. 2009 ; Vol. 113, No. 1. pp. 137-144.
@article{702e7baa90e84289b32088fe3af7b9bc,
title = "Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93",
abstract = "Introduction: International Breast Cancer Study Group (IBCSG) Trial 11-93 is the largest trial evaluating the role of the addition of chemotherapy to ovarian function suppression/ablation (OFS) and tamoxifen in premenopausal patients with endocrine-responsive early breast cancer. Methods: IBCSG Trial 11-93 is a randomized trial comparing four cycles of adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to OFS and 5 years of tamoxifen versus OFS and tamoxifen without chemotherapy in premenopausal patients with node-positive, endocrine-responsive early breast cancer. There were 174 patients randomized from May 1993 to November 1998. The trial was closed before the target accrual was reached due to low accrual rate. Results: Patients randomized tended to have lower risk node-positive disease and the median age was 45. After 10 years median follow up, there remains no difference between the two randomized treatment groups for disease-free (hazard ratio = 1.02 (0.57-1.83); P = 0.94) or overall survival (hazard ratio = 0.97 (0.44-2.16); P = 0.94). Conclusion: This trial, although small, offers no evidence that AC chemotherapy provides additional disease control for premenopausal patients with lower-risk node-positive endocrine-responsive breast cancer who receive adequate adjuvant endocrine therapy. A large trial is needed to determine whether chemotherapy adds benefit to endocrine therapy for this population.",
keywords = "Breast cancer, Estrogen receptor, Goserelin, Ovarian ablation, Ovarian function suppression, Tamoxifen",
author = "Beat Th{\"u}rlimann and Price, {Karen N.} and Gelber, {Richard D.} and Holmberg, {Stig B.} and Diana Crivellari and Marco Colleoni and John Collins and Forbes, {John F.} and Monica Castiglione-Gertsch and Coates, {Alan S.} and Aron Goldhirsch",
year = "2009",
month = "1",
doi = "10.1007/s10549-008-9912-9",
language = "English",
volume = "113",
pages = "137--144",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93

AU - Thürlimann, Beat

AU - Price, Karen N.

AU - Gelber, Richard D.

AU - Holmberg, Stig B.

AU - Crivellari, Diana

AU - Colleoni, Marco

AU - Collins, John

AU - Forbes, John F.

AU - Castiglione-Gertsch, Monica

AU - Coates, Alan S.

AU - Goldhirsch, Aron

PY - 2009/1

Y1 - 2009/1

N2 - Introduction: International Breast Cancer Study Group (IBCSG) Trial 11-93 is the largest trial evaluating the role of the addition of chemotherapy to ovarian function suppression/ablation (OFS) and tamoxifen in premenopausal patients with endocrine-responsive early breast cancer. Methods: IBCSG Trial 11-93 is a randomized trial comparing four cycles of adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to OFS and 5 years of tamoxifen versus OFS and tamoxifen without chemotherapy in premenopausal patients with node-positive, endocrine-responsive early breast cancer. There were 174 patients randomized from May 1993 to November 1998. The trial was closed before the target accrual was reached due to low accrual rate. Results: Patients randomized tended to have lower risk node-positive disease and the median age was 45. After 10 years median follow up, there remains no difference between the two randomized treatment groups for disease-free (hazard ratio = 1.02 (0.57-1.83); P = 0.94) or overall survival (hazard ratio = 0.97 (0.44-2.16); P = 0.94). Conclusion: This trial, although small, offers no evidence that AC chemotherapy provides additional disease control for premenopausal patients with lower-risk node-positive endocrine-responsive breast cancer who receive adequate adjuvant endocrine therapy. A large trial is needed to determine whether chemotherapy adds benefit to endocrine therapy for this population.

AB - Introduction: International Breast Cancer Study Group (IBCSG) Trial 11-93 is the largest trial evaluating the role of the addition of chemotherapy to ovarian function suppression/ablation (OFS) and tamoxifen in premenopausal patients with endocrine-responsive early breast cancer. Methods: IBCSG Trial 11-93 is a randomized trial comparing four cycles of adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to OFS and 5 years of tamoxifen versus OFS and tamoxifen without chemotherapy in premenopausal patients with node-positive, endocrine-responsive early breast cancer. There were 174 patients randomized from May 1993 to November 1998. The trial was closed before the target accrual was reached due to low accrual rate. Results: Patients randomized tended to have lower risk node-positive disease and the median age was 45. After 10 years median follow up, there remains no difference between the two randomized treatment groups for disease-free (hazard ratio = 1.02 (0.57-1.83); P = 0.94) or overall survival (hazard ratio = 0.97 (0.44-2.16); P = 0.94). Conclusion: This trial, although small, offers no evidence that AC chemotherapy provides additional disease control for premenopausal patients with lower-risk node-positive endocrine-responsive breast cancer who receive adequate adjuvant endocrine therapy. A large trial is needed to determine whether chemotherapy adds benefit to endocrine therapy for this population.

KW - Breast cancer

KW - Estrogen receptor

KW - Goserelin

KW - Ovarian ablation

KW - Ovarian function suppression

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=58049196789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049196789&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-9912-9

DO - 10.1007/s10549-008-9912-9

M3 - Article

C2 - 18259856

AN - SCOPUS:58049196789

VL - 113

SP - 137

EP - 144

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -